Evaluation of predictability for vancomycin dosage regimens by the bayesian method with Japanese population pharmacokinetic parameters

Biological and Pharmaceutical Bulletin

Volumn 25, Issue 10, 2002, Pages 1333-1338

  Teramachi, Hitomi ^a   Hatakeyama, Hiromi ^a   Matsushita, Ryo ^b   Imai, Yukio ^a   Miyamoto, Ken'ichi ^c   Tsuji, Akira ^b  

^a Kouseiren Chu nou Hospital   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Bayesian method; Distribution volume; Dosage regimen; MRSA; Vancomycin

Indexed keywords

CREATININE; VANCOMYCIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BAYES THEOREM; CALCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INFUSION; JAPAN; MALE; POPULATION RESEARCH; PREDICTION; STEADY STATE; TIME; BLOOD; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DRUG SCREENING; METHODOLOGY; MIDDLE AGED; PREDICTION AND FORECASTING;

ADULT; AGED; AGED, 80 AND OVER; BAYES THEOREM; CONFIDENCE INTERVALS; DRUG EVALUATION; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; VANCOMYCIN;

EID: 0036781257     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.25.1333     Document Type: Article

References (20)

1. Rybak M. J., Albrecht L. M., Boike S. C., Chandrasekar P. H., J. Antimicrob. Chemother., 25, 679-687 (1990).
2. Takahashi S., Jpn. J. TDM, 14, 208-216 (1997).
3. Takahashi S., Nagayama Y., Yoshino C., Horiguchi H., Saito N., Takano Y., Yamazaki A., Koakutsu H., Kobayashi T., Sako K., Shinozaki K., Jpn. J. TDM, 17, 377-382 (2000).
4. Igarashi M., Nakatani R., Hayashi M., Nakata K., Kasuya Y., Jpn. J. Chemother., 48, 545-552 (2000).
5. Andres I., Lopez R., Pou L., Pinol F., Pascual C., Ther. Drug Monit., 19, 614-619 (1997).
6. Sato M., Shinozaki K., Kojima T., Sako K., Atsuda K., Jpn. J. TDM, 18, 286-290 (2001).
7. Maeda Y., Kiribayashi Y., Konishi T., Yokote T., Funakoshi S., Nii K., Tsukiai S., Takahashi M., Eno S., Maruhashi A., Jpn. J. Hosp. Pharm., 20, 279-287 (1994).
8. Pea F., Porreca L., Baraldo M., Furlanut M., J. Antimicrob. Chemother., 45, 329-335 (2000).
9. Polard F., Bouquin V. L., Corre P. L., Kerebel C., Trout H., Feuillu A., Verge R. L., Malledant Y., Ther. Drug Monit., 21, 395-403 (1999).
10. Yasuhara M., Iga T., Zenda H., Okumura K., Oguma T., Yano Y., Hori R., Ther. Drug Monit., 20, 139-148 (1998).
11. Cockcroft D. W., Gault M. H., Nephron, 16, 31-41 (1976).
12. Kelman A. W., Whiting B., Bryson S. M., Br. J. Clin. Pharmac., 14, 247-256 (1982).
13. Yano Y., Oguma T., Jpn. J. TDM, 14, 179-188 (1997).
14. Winter M. E., "Basic Clinical Pharmacokinetics," 3rd ed. by Koda-Kimble M. A., Applied Therapeutics. Inc., Vancouver, WA, 1994, pp. 474-499.
15. Cantu T. G., Yamanaka-Yuen N. A., Lietman P. S., Clin. Infect. Dis., 18, 533-543 (1994).
16. Sheiner L. B., Beal S. L., J. Pharmacokinet. Biopharm., 9, 503-512 (1981).
17. Matsuno T., Shimura E., Ito K., Han S., Mizutani Y., Fujii H., Ishizuya O., Takahashi M., Okano Y., Shima K., Jpn. J. TDM, 17, 71-78 (2000).
18. Teramachi H., Yamashita H., Imai Y., Hayakaya K., Yamato M., Jpn. J. Pharm. Health Care Sci., 27, 369-374 (2001).
19. Zaske D. E., "Applied Pharmacokinetics," 3rd ed. by Evance W. E., Schentag J. J., Jusko W. J., Applied Therapeutics, Inc., Vancouver, 1992. pp. 14-1-14-47.
20. Hurst A. K., Yoshinaga M. A., Mitani G. H., Foo K. A., Jelliffe R. W., Harrison E. C., Antimicrob. Agents Chemother., 34, 1165-1171 (1990).